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HIV and Vertebral Fractures: a 
Systematic Review and Metanalysis
Thales A. S. H. Ilha1, Fabio V. Comim  1,2, Rafaela M. Copes1,2, Juliet E. Compston3 &  
Melissa O. Premaor  1,2
The survival of HIV-infected patients has increased with the advent of antiretroviral therapy with 
the emergence of new comorbidities. Vertebral fracture is a manifestation of reduced bone strength 
and osteoporosis. This study aims to assess the frequency of spine fractures in HIV-positive men and 
women aged over 18 years. We performed a systematic review of randomized controlled trials, cohort 
studies, cross-sectional studies, and case-control studies. Studies that evaluated morphometric and/or 
clinical vertebral fracture were included. In total 488 studies were found, of which 53 had their full texts 
evaluated. A total of 85,411 HIV positive individuals were identified in 26 studies. The meta-analysis 
of the prevalence of vertebral fractures included 12 studies with 10,593 subjects. The prevalence was 
11.1% [95% confidence interval (95% CI) 4.5%, 25.0%, I2 98.2% p < 0.00001]. When we evaluated 
independently studies of clinical vertebral fracture and morphometric vertebral fracture, the prevalence 
was 3.9% (95% CI 0.9, 15.8, I2 96.4% p < 0.00001) and 20.2% (95% CI 15.7%, 25.6%, I2 69.9% p = 0.003) 
respectively. HIV-infected individuals had an odds ratio of vertebral fractures of 2.3 (95% CI 1.37, 3.85, 
I2 98.2% p < 0.00001) when compared with HIV-uninfected patients (n = 9 studies). In conclusion, HIV-
positive subjects had a higher risk of vertebral fractures when compared with HIV-negative subjects.
With the advent of antiretroviral therapy (ARV), the survival of HIV-positive individuals has increased1,2. 
Consequently, the spectrum of comorbidities they exhibit has increased3. Many of these comorbidities, common 
in the older population, arise at a younger age in individuals infected with HIV and one of the affected systems is 
the skeleton. Although studies showing the incidence and prevalence of fractures in HIV-infected patients have 
different designs concerning the sample size, age and gender, study population, type of fracture, and method of 
fracture assessment, the vast majority show a significant increase in the risk of fracture4. Reduction in bone min-
eral density (BMD) has been reported in HIV-infected patients regardless of sex and age, with an odds ratio of 6.4 
for reduced BMD and 3.7 for osteoporosis when compared with uninfected controls5.
Vertebral fractures are one of the most common manifestations of osteoporosis. Radiographically confirmed 
vertebral fractures are a sign of impaired bone quality and strength and a strong predictor of future vertebral and 
non-vertebral fractures6. The presence of one vertebral fracture is associated with a five-fold increase in the risk of 
subsequent vertebral fractures and a three-fold increase in hip fracture risk7. Most vertebral fractures are asymp-
tomatic, and only about one-fourth of incident radiographic vertebral deformities are clinically diagnosed8. The 
prevalence of vertebral fractures in the general population increases with age, occurring in approximately 25% of 
women over 50 years9.
Recently, studies have demonstrated an increased prevalence of vertebral fracture in HIV patients10–31. 
Although the studies that evaluate the risk of vertebral fractures in people living with HIV appear to be consistent, 
the studies that evaluate the prevalence and incidence of spine fractures have shown different results. Moreover, 
these studies have different designs, sample sizes, and fracture assessment, which make the findings of each study 
difficult to interpret and generalize. Thus, we have performed a systematic review and meta-analysis to quantify 
the prevalence, incidence, and risk of vertebral fractures in HIV-individuals. To the best of your knowledge, this 
is the first metanalysis evaluating spine fractures in people living with HIV.
Materials and Methods
The meta-analysis was carried out according to the PRISMA Guidelines32. The study was registered at PROSPERO, 
an international database of prospectively registered systematic reviews, with protocol number CRD42016048702 9 
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https://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42016048702). It was approved by the 
Research Committee of Health Sciences Centre of the Federal University of Santa Maria (045911).
Studies were included in the meta-analysis if they met the following criteria: (1) Randomized controlled trials, 
cohort studies, cross-sectional, and case-control; (2) men and women aged over 18 years, HIV-positive with or 
without antiretroviral therapy; (3) have evaluated both morphometric or clinical vertebral fracture; and (4) the 
primary outcome of interest was prevalence or incidence of vertebral fractures, and/or the secondary outcome 
was hazard ratio of fracture. Animal studies, studies that evaluated specific cohorts of patients with HIV (for 
example, studies that assess a particular variable only in patients e.g. HIV with hepatitis-C, or just HIV with lipo-
dystrophy), or those that did not meet the inclusion criteria were excluded from the initial review. The last search 
was on September 27th, 2017.
The search for studies was performed in EMBASE (Elsevier), PubMed, the Regional Library of Medicine 
(BIREME), and the Cochrane Library (Cochrane Database of Systematic Reviews - CDSR). Also, studies based on 
the reference lists of the included articles were analyzed. Studies written in any language and with no publication 
date limits were considered. The terms used for the search are described in the supplementary material.
Whenever different articles from the same database were obtained, all the articles necessaries to complete the 
extraction were included in the metanalysis. The authors were contacted by email when more data were required.
Selection process. The selection of the studies was performed by two protocol members independently. 
Firstly, the studies were screened based on their titles and abstracts. The studies that could not be ruled out in this 
procedure had their full texts evaluated. Additionally, for all selected items, the full texts were sought, and their 
eligibility was double-checked. If there was dis- agreement between the two reviewers regarding the identifica-
tion, eligibility, and inclusion of items, they were checked again by a third reviewer and, if necessary by a fourth 
reviewer.
Data collection process. The data of each study were extracted, independently, by two protocol members 
(TSI and RMC). The agreement between the two extractors should be 100%. In the cases where there was disa-
greement, a third and, if necessary, a fourth party adjudicated. The following data were extracted from each arti-
cle: the name of the first author, year of publication, study design, site, age, gender, ART use, number of vertebral 
fractures, method of vertebral fracture evaluation (clinical, morphometric, ICD, self-reported), and outcome 
(vertebral fracture prevalence, incidence, odds/hazard ratio). When any of these data could not be extracted from 
the full text of the study, the authors were contacted.
Risk of bias (quality) assessment. Assessment of the risk of bias of the included studies was performed 
independently by two authors and was ranked as high, low and uncertain. Possible discrepancies were adjudicated 
by the other protocol members. All included studies were cohort, randomized clinical trials, case–control, or 
cross-sectional studies. For RCTs and cohort or case-control studies, bias risk assessment was conducted by the 
Cochrane Collaboration tool33 and Newcastle-Ottawa scale34 respectively. The Newcastle-Ottawa scale assessed 
the selection, comparability and exposure of a case-control study and selection, comparability, and outcome of a 
cohort study. In it, 9 stars represent maximum score for a study, and the study with over 6 stars would be regarded 
as relatively high quality. For cross-sectional study assessment quality Crombie´s Scale33 was used. Crombie´s 
Scale is composed of 7 items, and each item is graded as “Yes” (1 point), “Unclear” (0.5 points), or “No” (0 points).
Vertebral fracture definition. There are differing criteria for the definition of vertebral fracture and thus 
rates may vary within the same population depending on the approach selected. In addition, some studies use just 
ICD coding to detect the incidence or prevalence of vertebral fracture, which restricts data to inclusion only of 
fractures that present clinically. Because of the heterogeneity of methods used for vertebral fracture assessment 
among the studies, for the purposes of this analysis we separated the studies into two groups according to the 
approach utilised. Studies that used imaging methods (X-ray, DXA or CT), independent of protocol, were allo-
cated to the morphometric vertebral fracture group. Studies that used ICD, self-report, or did not describe the 
method of vertebral fracture assessment were allocated to the clinical vertebral fracture group.
Data synthesis and statistical analysis. Data on the prevalence, incidence, and the odds ratio of ver-
tebral fracture were summarized separately. We pooled proportions (data for prevalence or incidence) applying 
LOGIT transformation, using random effects model, with DerSimonian and Laird as variance estimator35. Results 
were presented as a pooled proportion (prevalence or incidence), with 95% confidence intervals. The pooled odds 
ratio was estimated, also using random effects model, with DerSimonian and Laird as variance estimator35. The 
statistical heterogeneity among studies was assessed using Cochran’s Q test and the inconsistency I2 test36. We 
performed an additional analysis with a fixed-effects model to qualitatively evaluate differences in point estimates 
provided by models with random and fixed effects. For sensitivity analysis, to explain heterogeneity and poten-
tial effects modifiers, we performed subgroup analysis for the type of fracture assessment and type of study, and 
meta-regression for age, gender, study location, sample size, study year, and study quality using a mixed-effects 
model (with the explaining variable as fixed)37,38. The publication bias was evaluated thru a qualitative inspection 
of funnel plot39 and the Begg test as a statistical parameter for testing funnel plot asymmetry40. All the analyses 
were made using the software R [R version 3.2.4, 2016, The R Foundation for Statistical Computing, Platform: 
x86_64-apple-darwin13.4.0 (64-bit)] and RStudio [RStudio Team (2015). RStudio: Integrated Development for 
R. RStudio, Inc., Boston, MA http://www.rstudio.com/].
Approval, Registration and Availability. Approval for this study was obtained from the Research 
Committee of Health Sciences Centre of the Federal University of Santa Maria (045911). The study protocol is 
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registered with the International Prospective Register of Systematic Reviews (PROSPERO) under the number 
CRD42016048702. All research data will be available upon publication at https://www.dcmufsm.com.
Results
Study selection. In total 488 studies were found in the electronic database search, of which 90 were dupli-
cates. After screening the title and abstracts, 53 relevant studies remained and underwent detailed full-text review. 
Of these, 29 were excluded due to lack of a suitable outcome, inappropriate study design, inclusion of selected 
cohorts of patients with HIV, or redundant publication. A total of 24 articles met the eligibility criteria and were 
included in the meta-analysis. The process of relevant studies selection and the number of articles excluded at 
each stage are outlined in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 
flow diagram (Fig. 1). In two different studies from the same author, carried out with the same cohort, the results 
were overlapping25,26. To achieve full information from this population, data were extracted from both articles and 
the values were pooled and analyzed together.
Study characteristics. Table 1 describes the study characteristics of the 24 studies included in our 
meta-analysis. A total of 84,628 individuals HIV positive were identified in 24 studies. We found 10 cross-sectional 
studies with a total of 1,221 subjects; 10 cohort studies with 74,116; 3 case-control studies with 8,689 and 1 ran-
domized clinical trial with 602. For vertebral fracture ascertainment, 9 studies used imaging methods, 7 used 
ICDs or databases, 4 used self-reported questionnaires, 1 used clinical charts, and 2 did not describe the method 
used. Seventeen studies recruited male and female participants, 5 studies recruited only males, and 2 studies 
recruited only females. Most of the subjects in the studies were taking antiretroviral therapy. Apart from the study 
conducted by Gallant et al.17, which was a multicenter study enrolling participants from several countries (South 
America, Europe, USA), the studies took place in individual countries: 8 from Italy, 7 from USA, 2 from Denmark 
and one each from Taiwan, France, Australia, UK and Japan.
Study quality. The Newcastle-Ottawa Scale was applied to assess the selection, comparability, and expo-
sure of the case-control and cross-sectional study, and the selection, comparability, and outcome of the cohort 
study. These scores are displayed in Table 4 (Supplementary material). The Crombie’s items assessment for 
cross-sectional studies is described in Table 5 (Supplementary material).
HIV and vertebral fracture. Twelve studies were used in the assessment of the prevalence of vertebral 
fracture in HIV-positive subjects (Fig. 2). The mean age of the included subjects varied from 40 to 53 years. Two 
Figure 1. PRISMA 2009 Flow Diagram of the studies included in the review. The meta-analysis was carried out 
according to the PRISMA Guidelines32.
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subgroups were evaluated independently: clinical vertebral fracture and morphometric vertebral fracture, with 5 
and 7 studies, respectively. The overall prevalence was 11.1% (95% confidence interval 4.5% to 25.0%; prediction 
interval 0.3% to 85.6%). The prevalence of morphometric vertebral fracture was 20.2% (95% confidence interval 
15.7 to 25.6; prediction interval 8.8% to 39.6%), and of clinical vertebral fracture 3.9% (95% confidence interval 
0.9 to 15.8; prediction interval 0.02% to 91.6%). The p-value for the publication bias evaluated by the Begg test 
was 0.131. The funnel plot is displayed in Figure 4, supplementary material. There were no major differences in 
the point estimates provided by models with random and fixed effects (data not shown).
A sensitivity analysis was carried out to investigate the effect of each study on results of the meta-analysis of 
the prevalence of vertebral fracture. We excluded the included articles one by one; however, the pooled results 
were not affected by this procedure and no single article could explain the source of the heterogeneity.
The meta-analysis of the incidence of vertebral fractures included 10 studies with 422,799 PY HIV- infected 
individuals. The pooled estimate of the incidence was 0.8 (95% confidence interval 0.4 to 1.9) per 1000 
person-years. The assessment for heterogeneity was significant for vertebral fractures (Q = 1.459, p = 0.0001, 
I² = 95.9%). However, when we excluded one outlier study (Young et al. 2011), the incidence estimate decreased 
to 0.6 (95% confidence interval 0.4 to 0.8) per 1000 person-years and the heterogeneity remained significant, but 
lower (Q = 0.194, p = 0.0001, I² = 74.9%). The incidence rate of each study is described in Table 2.
In a total of 9 studies, 56,117 HIV-infected patients were compared with 517,1132 HIV-uninfected controls. 
HIV patients had a 2.3-fold increase in the odds ratio of vertebral fracture (95% confidence interval 1.37 to 3.85) 
when compared with HIV-uninfected patients (Fig. 3). There was no interaction between the assessment method 
[morphometric or clinical vertebral, P = 0.211] and the study type (case-control and cross-sectional, P = 0.918]; 
(data not shown). The p-value for the publication bias evaluated by the Begg test was 0.421. The funnel plot is 
displayed in Figure 4, supplementary material. There were no major differences in the point estimates provided 
by models with random and fixed effects (data not shown).
Meta-regression. The results for the meta-regression of the prevalence analysis are shown in Table 3. There 
was no interaction between age, gender, and study year and the prevalence of vertebral fractures. Nonetheless, the 
heterogeneity was explained, at least in part, by the study location, sample size, and study quality.
Author Year Study design Site Age (years) Gender (%)
Recruitment 
time (years of 
follow-up) ART(%) VF ascertainment
Bedimo12 2012 Cohort USA 18–70+ 98% male 1988–2009 (21) 69.4% ICD
Borderi13 2014 Cross-sectional Italy 51 (31–67) 68% male NA 86.13% Semiquantitative/Morphometric
Ciullin14 2017 Cross-sectional Italy 43 (37–52) 87.2% male NA 93.6% Semiquantitative/Morphometric
Clò15 2015 Cross-sectional Italy 47 (24–72) 64.15% male NA — Lateral spine x-ray
Collin16 2009 Cohort France 36.2 77.2% male 1997–2009 (7.1) 100% —
Gallant17 2004 RCT
South 
America, 
Europe, USA
36 73.92% male 48 weeks 100% Lateral spine x-ray
Gazzola10 2015 Cross-sectional Italy 49 (40–51) 73%male NA 70.61% Semiquantitative/Morphometric
Hansen18 2012 Cohort Denmark 36.7 (30.5–44.5) 76% male 1995–2009 (14) 78% ICD
Kurita19 2014 Cohort Japan 15–81 92.8% male 2005–2010 (5) 65,9% —
Mazzotta20 2015 Cross-sectional Italy 44.2 ± 10 70.6% male NA 79.7% Self-reported
Pepe49 2012 Cross-sectional Italy 48.6 (40–69) 100% male NA 100% Semiquantitative
Porcelli11 2014 Cross-sectional Italy 51 (36–75) 71% male NA 100% Semiquantitative/Morphometric
Prieto-Alhambra21 2014 Case-control Denmark 43.4 ± 27.4 51.8% female 2009 (1) — ICD
Sharma22 2015 Cohort USA 40 (34–46) 100% female 2002–2013 (10) 63% Self-reported
Short50 2014 Cross-sectional UK 45 (38–51) 100% male NA 78% Self-reported
Torti23 2012 Cross-sectional Italy 53 (42–71) 100% male NA 78.12% Semiquantitative/Morphometric
Triant24 2008 Case- control USA 20–79 65.16% male 1996–2008 — ICD
Womack*,25,26 2011/2013 Cohort USA 53 (48–61) 100% male 1997–2009 (6 ± 3.9) 75% ICD
Yang27 2012 Cohort Taiwan <20–>60 76.9–90.1% male 2005–2008 — ICD
Yin28 2012 Cohort USA 39 (33–45) 83% male (5) 99.69% Self-reported
Yin29 2010 Cross-sectional USA 55.9 ± 0.7 100% female 2002–2007 79.34% Semiquantitative
Yong30 2011 Case-control Australia 49.8 88.54% male 1998–2009 (10.5) 80.32% ICD/Victorian HIV Database
Young31 2011 Cohort USA 40 (34–46) 79% male 2000–2008 72.7% Self-reported /HOPS electronic databases
Table 1. Studies characteristics. —=information not given; NA = not assessed; RCT = Randomized Clinical 
Trial; ICD = International Code Diseases; *The data were extracted from two different articles with the same 
cohort.
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Discussion
This systematic review included 24 studies, with 84,628 HIV-infected subjects. The pooled results indicated that 
HIV infection was associated with an increase in the risk of vertebral fracture. When compared with HIV-negative 
subjects, HIV patients had a 2.3-fold increased risk of vertebral fracture, independent of age and gender.
Previous studies have shown that HIV infection has adverse effects on bone health. In 2006, a meta-analysis 
of cross-sectional studies reported an odds ratio of 6.4 for reduced BMD and 3.7 for osteoporosis, defined as a 
BMDT-score ≤−2.5 in HIV-infected subjects compared with uninfected controls5. In another meta-analysis, 
Shiau et al.41 found a modest increase in the incidence of fracture in HIV-infected individuals, with an incidence 
rate ratio of 1.35 (95% CI 1.10–1.65) for fragility fracture and 1.58 (95% CI 1.25–2.00] for any fracture.
The exact mechanisms underlying bone disease in the HIV-infected population remain unclear. Risk factors 
for fracture include many of those seen in the general population, for example smoking, alcohol abuse, and gluco-
corticoid therapy, as well as HIV-specific risk factors such as anti-retroviral therapy, co-infection with hepatitis C, 
and hypogonadism. In addition, co-morbidities associated with HIV infection such as renal disease and diabetes 
also increase fracture risk42.
In our study, the meta-regression did not show an association between age or gender and vertebral frac-
ture. Although individual studies have included older subjects, the age range in the analyzed studies in our 
Figure 2. Forest plot of the prevalence of vertebral fractures in HIV-positive subjects. The proportions were 
pooled applying LOGIT transformation, using random effects model, with DerSimonian and Laird as variance 
estimator. Results were presented as a pooled prevalence, 95% confidence intervals. The p-value for subgroup 
analysis on the differences of the prevalence by type of fracture assessment is 0.021.
Cohort Persons/Years Incident Vertebral Fracture* 95% - CI
Bedimo et al.12 305237 0.4 0.3–0.5
Collin et al.16 6380 0.5 0.1–1.4
Gallant et al.17 1533 0.7 0.0–3.6
Hansen et al.18 29348 0.6 0.4–1.0
Kurita et al.19 2805 0.7 0.1–2.6
Sharma et al.22 22520 1.2 0.8–1.7
Yang et al.27 12898 0.5 0.2–1.0
Yin et al.28 23200 0.3 0.1–0.6
Yong et al.30 25452 0.7 0.4 -. 1.1
Young et al.31 1216 14.8 8.8–23.3
Total 430589 0.8 0.4–1.8
Table 2. Details of Incidence Vertebral Fracture by Cohort. *Per 1.000 persons/years; CI = confidence interval.
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meta-regression was from 40 to 53 years, which may have contributed to this finding. The positive association 
between age and vertebral fracture prevalence in the general population has been well documented in several 
large population-based studies43. The narrow age range in our study could have blunted this association.
The influence of gender on vertebral fractures in the general population appears to vary with age. Studies that 
include men and woman have reported that the incidence is higher in men than women under the age of 50–55 
years43. For men and woman aged 50–79 years, data from European Vertebral Osteoporosis Study (EVOS)44 have 
shown that the prevalence of vertebral fracture in the age-standardized population in Europe was 12.2% and 12% 
respectively. Other studies show that the risk rises in women after the age of 60 years and substantially after 70 
years of age45. There was no interaction between gender and vertebral fracture in our study.
Although the vast majority of the subjects in the studies evaluated in this systematic review and meta-analysis 
were on ART, the type and the duration of therapy were not described in several studies; therefore, we could not 
study its influence on vertebral fractures. The effects of ART on bone mineral density in HIV infected individ-
uals are well documented, with losses of between 2% and 6% during the first year of therapy and a tendency to 
stabilise thereafter, this effect varying with the drugs used. Bolland et al.46 investigated temporal changes in BMD 
of adults with HIV in longitudinal studies. The authors found that BMD was stable in HIV cohorts established 
on antiretroviral therapy, whereas cohorts initiating therapy had short-term accelerated BMD loss followed by 
a longer period of stability. To examine whether ART initiation is associated with increased fracture rate, Yin28 
evaluated the incidence of fracture in HIV-positive subjects from 26 randomized ART studies (n = 4640) followed 
in the AIDS Clinical Trials Group (ACTG) Longitudinal-Linked Randomized Trial study for 5 years. The authors 
found that in ART-naive subjects, fracture rates were higher in the first 2 years after ART initiation [(0.53/100 
person-years) when compared to the subsequent years (0.30/100 person-years)]. Nonetheless, the data on verte-
bral fracture incidence after initiation ART are sparse. In addition, most studies did not include morphometric 
evaluation of vertebral fractures.
The disparity between the prevalence of morphometric (20.2%) and clinical vertebral fractures (3.9%) in our 
study is in agreement with findings in the general population. Clinical vertebral fracture rates are considerably 
lower than radiographic vertebral fracture rates, reflecting the minority of these fractures that come to clinical 
Figure 3. Forest plot of the odds ratio of vertebral fractures in HIV-positive subjects. The pooled odds ratio 
was estimated using random effects model, with DerSimonian and Laird as variance estimator. Results were 
presented as a pooled odds ratio, 95% confidence intervals. The p-value for subgroup analysis on the differences 
of the prevalence by type of fracture assessment is 0.211.
Subgroups
No of 
studies RP
Summary effects
(95% CI) p Value
Heterogeneity
I², % p Value
Meta-regression for age Age (years) 12 0.07 −0.18, 0.34 0.553 98.31 <0.0001
Meta-regression for gender Male 12 −0.01 −0.06, 0.05 0.846 97.70 <0.0001
Meta-regression for study location Italy* 12 −1.02 −1.36, −0.67 <0.0001 79.22 <0.0001
Meta-regression for sample size n 12 −0.0003 −0.0005, −0.0002 <0.0001 82.06 <0.0001
Meta-regression for study year Year 12 0.22 −0.06, 0.50 0.192 95.06 <0.0001
Meta-regression for study quality Moderate quality** 12 −1.74 −2.95, −0.54 0.0045 92.81 <0.0001
Table 3. Meta-regression analysis of the prevalence rate covariates. Main results of the meta-regression. 
C-C = case control studies; C-S = cross-section studies; VF = vertebral fractures; RP = prevalence ratio; *when 
compared with UK; **when compared with high quality.
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attention47. In the general population, the prevalence of morphometric vertebral fractures in people age 50 years 
and over varies between 9.5 and 37%43,47, the value increasing with age and also varying according to the defini-
tion of vertebral fracture. In the EVOS study, the prevalence varied from 12.2% for men and 12% for women using 
the McCloskey method to 20.2% and 20.2%, respectively, when the Eastell method was used. In our analysis, stud-
ies using semiquantitative and quantitative methods were pooled together. This approach might have generated 
a conservative bias, underestimating the frequency of fractures. Studies that used the semiquantitative method 
could have missed mild fractures, classified as grade 1 by Genant48 because of the difficulty of detecting this type 
of fracture in younger individuals.
In our study, the data for vertebral fracture incidence were obtained from 10 studies. Nine of them used ICD 
data or self-reporting. Since only around one third of vertebral fractures are symptomatic, use of self-reporting 
data will underestimate the incidence. Furthermore different coding is used in ICD9 and ICD10, which may have 
contributed to the variation in reported incidence. The most recent version of ICD 10 defines several subtypes of 
vertebral fractures, and depending on the coding used by each study, different types and sites of vertebral fracture 
may be included. Hence, high impact fractures or fractures in cervical vertebrae may be included. Furthermore, 
the incidence ratio found in our study should be interpreted with caution as there were insufficient data to provide 
a robust estimate.
Our study has some limitations. It is a systematic review and meta-analysis of observational studies that aimed 
to evaluate the frequency and risk of vertebral fractures, therefore it is to be expected that our pooled analysis 
showed heterogeneity. Differences in the design of the studies, the study location, the sample size, the populations 
studied, the method used for vertebral fracture evaluation, and the quality of the studies may all have contrib-
uted to the observed heterogeneity. Another limitation is the fact that we included cohort, case-control, and 
cross-sectional studies in the estimated odds ratio, thus causality may not be concluded. Nevertheless, there was 
no interaction between the study type or method used for fracture and the pooled odds ratio of spine fractures. 
Finally, some studies included in our systematic review were not specifically designed to evaluate vertebral frac-
ture and/or vertebral fracture was not the primary endpoint. Because many vertebral fractures are asymptomatic, 
they might be underreported in those studies. Hence the prevalence of clinical vertebral fractures and the inci-
dence of vertebral fractures may be underestimated in our metanalysis.
Our study demonstrates that the risk of vertebral fracture in HIV-positive subjects is approximately double 
that of HIV-negative subjects, a finding that has important clinical implications. Although the risk factors for 
vertebral fractures have not been clearly established in the ‘HIV infected population, identification and correction 
of risk factors recognized in other populations, such as smoking, alcohol abuse, sedentary lifestyle, vitamin D 
deficiency, and the use of glucocorticoids should be recommended. Moreover, screening for spine fractures with 
X-ray should be considered in high risk individuals. Further studies are required to establish vertebral fracture 
incidence in HIV-positive individuals, to identify the risk factors involved, and to develop effective strategies for 
their prevention
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